A Phase 1, First-In-Human, Dose Escalation Study Of JNJ-67571244 (Bispecific Antibody Targeting CD33 And CD3) In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)